Principal Sterility Assurance Engineer
Prepared for · · Release record ↓
Experience
Sterility assurance across drug, device, and combination-product environments.
Sterility Assurance leader with a decade of experience advancing multi-modality sterilization programs, validation strategy, and ISO-aligned sterility systems across drug, device, and combination-product environments. Known for deep technical expertise in aseptic processing, EO, moist heat, and radiation sterilization; data-driven validation leadership; and the ability to translate complex standards into practical, scalable solutions. Strong record guiding IQ/OQ/PQ execution, evaluating material compatibility, mentoring technical teams, and supporting regulatory inspections and supplier audits.
Role 1 of 4 · 2016–2021
Sterilization Validation Quality Engineer
August 2016 – June 2021Ogden, UT
Led sterilization validation activities for drug and device products and served as sterility assurance SME for two US heat-sensitive small-molecule parenteral drug facilities.
Solutions in flexible bags, terminally sterilized by moist heat: F0 must clear a lethality floor at the cold spot and stay under a product-quality ceiling.
Led a team of seven through the start-up of a new parenteral line, establishing its sterility assurance program, sterilizer commissioning, process development, and FAT/IQ/OQ/PQ.
Supported, then led, dose setting, dose mapping and dose audits for in-house radiation sterilization.
A VDmax method, built on the product's bioburden, substantiates the sterilization dose; the map finds Dmin, which must reach it, and Dmax, which the materials must tolerate.
Prepared thermal and biologically inoculated test samples, analyzed study and production data, wrote qualification reports, and supported routine batch record review and release.
Thermocouples find the load's cold spot and the inoculated samples go there; routine release rests on the reviewed batch record plus the tests the process still requires.
Role 2 of 4 · 2021–2022
Quality Supervisor, Ethylene Oxide (EO) Sterilization
June 2021 – September 2022Sandy, UT
Directed and mentored a team of sterility assurance professionals, sustaining compliance for 300+ drug delivery products.
Defended sterility assurance and microbiology processes as front-room SME in several successful FDA inspections and notified body audits.
Consolidated seven legacy EO processes into one validated cycle.
A consolidated EO cycle is validated against the hardest-to-sterilize product or PCD it covers; residuals and material compatibility are still assessed product by product.
Led sterility assurance investigations for nonconformances, CAPAs and isolate identification.
Identifying what grew separates a lab or handling contaminant from the BI organism or product flora, and each points to a different cause.
Managed biological indicators, PCD production and cycle development, and piloted bioburden, sterility and residuals testing, requalifications and procedure reviews.
The PCD puts the BI (Bacillus atrophaeus for EO) where gas and moisture reach last; in common pH-indicator BIs, purple after incubation means no growth, and the unexposed control must grow yellow.
Role 3 of 4 · 2022–2026
Principal Engineer, Global Sterility Assurance
September 2022 – February 2026Round Lake, IL
Led sterility assurance strategy for a $42M/yr margin-improvement portfolio across 48+ sites, assessing design and process changes and writing validation and adoption protocols.
Guided drug and device projects with sterilization impact across sites, remotely and onsite, so cycle design, validation and documentation met global sterility requirements.
A change joins a validated family by an adoption protocol only if it is no harder to sterilize than the family's worst case; otherwise it is validated.
Partnered with cross-functional development and manufacturing teams to set sterilization parameters, define validation strategies, and build sterility requirements into project plans.
Mentored engineers, scientists and quality staff on terminal sterilization, aseptic fundamentals and contamination control strategy.
Role 4 of 4 · 2026
Senior Sterilization Supplier Quality Engineer
May 2026 – September 2026Northfield, IL
Evaluated sterilization documentation from contract sterilizers and manufacturers (EO, moist heat, dry heat, radiation, aseptic) and guided suppliers to close compliance gaps.
Sterilization run by a contract sterilizer is still the manufacturer's responsibility, so the supplier's validation and routine records are the evidence.
Contributed sterility assurance expertise to supplier audits and reviewed audit reports, working with suppliers to ensure CAPA responses were adequate and implementation was verified.
A CAPA is adequate when it fixes the system, and it closes only after implementation and effectiveness are verified.
Led cross-functional teams of quality, sourcing, business unit and supplier stakeholders to align on supplier risk, driving containment, new-project and disengagement decisions.
Drove continuous improvement by developing AI-assisted workflows that researched and assembled quality data in highly verifiable ways to reduce manual effort in record review.
Master of Science, Data AnalyticsWestern Governors University
Bachelor of Science, Applied PhysicsUniversity of Utah
Last record on the desk
Explore
Explore
Principal Sterility Assurance Engineer
Sterility Assurance leader with a decade of experience advancing multi-modality sterilization programs, validation strategy, and ISO-aligned sterility systems across drug, device, and combination-product environments. Known for deep technical expertise in aseptic processing, EO, moist heat, and radiation sterilization; data-driven validation leadership; and the ability to translate complex standards into practical, scalable solutions. Strong record guiding IQ/OQ/PQ execution, evaluating material compatibility, mentoring technical teams, and supporting regulatory inspections and supplier audits.
Master of Science, Data Analytics — Western Governors University
Bachelor of Science, Applied Physics — University of Utah
EO (ISO 11135) · Radiation (ISO 11137) · Moist Heat (ISO 17665) · AAMI CISS · Aseptic Processing · Validation (IQ/OQ/PQ, CSV) · Sterility Assurance Systems · Microbiology & Bioburden · Contract Sterilization · Supplier Audits & CAPA · GMP & Inspections · Risk Management · Change Control · Nonconformances & RCA · Sterile Barrier Packaging · Project Management · Training and Coaching · Statistics & SPC · Data Analysis & Visualization · AI & Process Automation
A positive BI is investigated before it is explained, and before the load is dispositioned. The growth is identified to species and compared with the BI organism; a morphology match alone can’t tell them apart. A false positive needs evidence: a different organism, and a way in.
The BI organism, grown from an intact vial that was handled cleanly, is a real survivor and a process signal. The load is held, and the cycle, the load, the PCD and the BI lot are all examined, even when every parameter was in range. The unexposed positive control has to grow, or the run’s no-growth results can’t be trusted.
In Grade A, any growth is investigated, and EU GMP Annex 1 expects Grade A and B isolates to be identified to species. The identity points to the source: skin cocci to people, gram-negative rods to water, spore formers and moulds to materials, dust and air.
A CAPA goes after the cause, not the single event, and closes only when its effectiveness is verified (ISO 13485, clause 8.5.2). Identification methods: USP <1113>. Interpreting BI results: ISO 11138-7.
The BI organisms: Bacillus atrophaeus for EO; commonly Geobacillus stearothermophilus for moist heat; Bacillus subtilis for some low-F0 moist-heat cycles. Brevundimonas diminuta is the challenge organism for sterilizing-grade filters.
The cases are illustrative.
Led sterility assurance investigations for nonconformances, CAPAs and isolate identification.
chamber spread: heat-up, then exposuredashed: allowed band
Illustrative.
Led a team of seven through the start-up of a new parenteral line, establishing its sterility assurance program, sterilizer commissioning, process development, and FAT/IQ/OQ/PQ.
Prepared thermal and biologically inoculated test samples, analyzed study and production data, wrote qualification reports, and supported routine batch record review and release.
Illustrative.
A contract sterilizer runs an outsourced process. The device maker stays responsible for it and controls it through a quality agreement and purchasing controls (ISO 13485:2016, 4.1.5 and 7.4). The certificate of processing is the sterilizer’s summary. The cycle or irradiation record is the evidence behind it.
For EO, conventional release under ISO 11135 rests on the process records and the BI results. Releasing without BIs needs a process validated for parametric release. The BIs are read after incubation, and a positive control from the same lot has to grow.
For electron beam, the process parameters are the beam (energy, current, scan width) and the conveyor speed. Routine dosimeters sit at a monitoring position, and dose mapping gives the ratios that turn their readings into the minimum and maximum dose in the product. Both have to sit inside the specified range: the sterilization dose is the floor, and the maximum acceptable dose from material qualification is the ceiling (ISO 11137-1).
A number on a page is only as good as where it came from: which sensor or dosimeter, whether its calibration was current, and which cycle it belongs to. A mismatch between certificate and record, even one digit, is resolved before release.
Evaluated sterilization documentation from contract sterilizers and manufacturers (EO, moist heat, dry heat, radiation, aseptic) and guided suppliers to close compliance gaps.
Drove continuous improvement by developing AI-assisted workflows that researched and assembled quality data in highly verifiable ways to reduce manual effort in record review.
Illustrative.
Illustrative.
Bioburden comes first: ten items from each of three batches, counted with a method whose recovery efficiency is known, and corrected for it (ISO 11737-1). The verification dose is read from ISO 11137-2 for that bioburden, normally from the overall average, or from the highest batch average when one batch averages at least twice the overall.
VDmax25 substantiates 25 kGy when every batch’s average bioburden is 1,000 CFU or less. Ten items take the verification dose and go to tests of sterility (ISO 11737-2), whole or as a validated sample item portion. No more than one positive is accepted; two call for a confirmatory ten, which must show none. The verification dose is set for a SAL of 10⁻¹, so an occasional positive is part of the design.
Above that bioburden, VDmax25 doesn’t apply and another method, such as Method 1 or Method 2, sets the dose. Method 1 takes a hundred items to the verification dose for a SAL of 10⁻², accepts no more than two positives, and then reads the sterilization dose for SAL 10⁻⁶ from its table, which can be above or below 25 kGy. A VDmax method for 15 kGy serves products with very low bioburden.
The dose then has to keep holding. Dose audits repeat the verification dose on product at set intervals, with a bioburden count alongside. ISO 11137-1:2025 asks for four a year, each no more than four months after the last. The interval can be stretched once audits and bioburden show a stable record, and goes back to four a year if bioburden trouble appears.
In a VDmax25 audit, one positive in ten passes and two call for a confirmatory ten. At three or more, a test or dosing error or a specific bioburden-related cause is corrected and the audit repeated; otherwise three to six positives mean the dose is augmented at once and set again by another method, and seven or more mean sterilization at that dose stops. Batches already processed are risk-assessed.
Bioburden counts are skewed, so trends are often charted on a log scale. A run rule, such as eight points in a row on one side of the centre line, picks up a shift before any single point crosses a control limit.
Counts, doses and results here are generated, not product data.
Supported, then led, dose setting, dose mapping and dose audits for in-house radiation sterilization.
AAMI TIR28:2016 (reaffirmed 2024) is the guidance for adding products to an EO process that is already validated. Under ISO 11135, a family is validated on its most challenging product, or on a PCD that is at least as hard to sterilize as anything in the family. A newcomer has to fit under that.
The comparison covers what makes EO lethality hard to deliver. Gas and moisture have to reach every surface, which depends on lumens and mated surfaces, materials, packaging and how densely the load is packed. Then there’s what has to be killed: how much bioburden, and how resistant, such as spore-formers.
What gets compared is the newcomer’s hardest-to-reach spot, not its average part. Length alone doesn’t decide it: a short dead-ended lumen can be harder to reach than a long open one.
Easier on one count doesn’t cancel harder on another. Lower bioburden doesn’t help gas get down a narrower lumen, so wherever something is harder, data settle it.
The data come from fractional exposures: short enough that some samples survive, run with the newcomer beside the family’s PCD. Whichever shows more positives is the harder to kill.
Lethality isn’t the whole adoption. Residuals are checked against the limits for the newcomer’s own patients and duration of use (ISO 10993-7:2026), and its materials against the cycle.
Where the line falls between a comparison and a new PQ is a documented judgement, not a count. The needle is illustrative.
Led sterility assurance strategy for a $42M/yr margin-improvement portfolio across 48+ sites, assessing design and process changes and writing validation and adoption protocols.
Illustrative.
EO dissolves into plastics during exposure and diffuses back out during aeration. Where EO meets a chloride source it can form ethylene chlorohydrin (ECH), which can go on forming while EO remains, is less volatile, and is slower to leave.
ISO 10993-7:2026 sets allowable limits for both on the device. In the 2026 edition, the limits and the extraction conditions follow the patient population and the duration of use, and a risk assessment may be used to set limits. Neonates and infants get tighter limits than adults. Duration of use sets both the limit and how the device is extracted. Devices with no body or user contact, and devices shown not to absorb EO or ECH, fall outside it.
Material matters most: how much gas a polymer takes up, and how fast it lets it go. Polyolefins take up little and release it quickly, and bring no chloride of their own. Plasticised PVC holds more, releases it slowly, and can supply the chloride that ECH needs. A warmer room speeds diffusion, within what the product and its packaging tolerate.
Residuals are only half of release. The sterility side, a cycle record inside its validated limits with BIs or parametric release, has to be in place too.
Each residual is drawn against its own limit, so one line serves both. The curves are illustrative, not material data.
Managed biological indicators, PCD production and cycle development, and piloted bioburden, sterility and residuals testing, requalifications and procedure reviews.
Illustrative.
Bags of solution are sterilized in a steam-air cycle. Air is added to the chamber on purpose, so the pressure outside each bag stays above the pressure building inside it as the solution heats and, above all, while it cools: the solution stays hot after the chamber has cooled.
Two probes ride in the load. The cold-spot probe sits in the slowest-heating position found in heat-penetration studies, and the exposure is timed from when it reaches the band. The other sits at the hottest position. F0 adds up the lethality each one sees, through heat-up, exposure and cool-down, as equivalent minutes at 121.1 °C with z = 10 °C.
For heat-sensitive solutions the cycle is bounded both ways: a lethality floor at the cold spot, and a ceiling at the hottest position set for product quality. The floor is lower than an overkill cycle’s, so it rests on the product’s bioburden and its resistance.
Release compares each record with the validated specification. A deviation is recorded, investigated against the validated limits and dispositioned before any decision on the load.
Prepared thermal and biologically inoculated test samples, analyzed study and production data, wrote qualification reports, and supported routine batch record review and release.
Drawings and models are illustrative.
A new edition does not undo a validation. It starts a documented gap assessment: what changed, whether it touches this product and process, and what closes the gap. Sometimes that is a written rationale, sometimes a procedure update, and sometimes new data.
ISO does not set transition periods; regulators do. When FDA recognizes a new edition, the entry names the date until which FDA still accepts declarations of conformity to the old one in premarket submissions. That governs what a new submission can cite, not whether an existing validation stands. In the EU, presumption of conformity under the MDR comes from harmonised standards whose references are published in the Official Journal.
The half-life shown is FDA’s transition where one is listed. For EU GMP Annex 1 and the QMSR it runs from publication to the date each applied. A replaced edition is withdrawn by its publisher; work done under it is judged by the gap assessment, not by a date.
Sources: each document’s foreword or scope; FDA Recognized Consensus Standards database and recognition lists 061, 062, 064 and 066, read 27 September 2026; the EU GMP Annex 1 document history; 89 FR 7496.
Known for deep technical expertise in aseptic processing, EO, moist heat, and radiation sterilization; data-driven validation leadership; and the ability to translate complex standards into practical, scalable solutions.
Every reaction is a link the table already holds: one standard relies on, cites or feeds the other. The line under each product is that link. A fizzle means only that the table holds no direct link between the two.
Accelerated aging (ASTM F1980) supports a shelf-life claim only with real-time aging running alongside to confirm it.
Method 1 and the VDmax methods of ISO 11137-2 start from a bioburden count, so the count has to be reliable: a validated recovery method, with counts corrected for it (ISO 11737-1).
ISO 10993-7:2026 sets residual EO and ECH limits by patient population and duration of use, and allows a risk assessment to set limits.
Editions shown are the current ones: ISO 11135:2014 + Amd 1:2018, ISO 11137-1:2025, ISO 11137-2:2013 + Amd 1:2022, ISO 17665:2024, ISO 10993-7:2026, ISO 11607-1:2019 + Amd 1:2023 and EU GMP Annex 1 (2022).
EO (ISO 11135) · Radiation (ISO 11137) · Moist Heat (ISO 17665)
Known for deep technical expertise in aseptic processing, EO, moist heat, and radiation sterilization; data-driven validation leadership; and the ability to translate complex standards into practical, scalable solutions.
On the desk
Standards
Records
In an inspection the front room is where the investigator asks and the subject-matter expert answers. The back room is where the records are found and checked before they go across the table.
FDA inspects device makers against the Quality Management System Regulation, 21 CFR 820, in effect since 2 February 2026, which incorporates ISO 13485 by reference. Makers of drugs are held to the cGMPs in 21 CFR 211, which require sterilization processes to be validated.
In the EU a notified body assesses devices under the Medical Device Regulation, commonly through Annex IX: an audit of the quality management system and an assessment of the technical documentation.
Defended sterility assurance and microbiology processes as front-room SME in several successful FDA inspections and notified body audits.
Contract EO sterilizer · CAPA responses. Illustrative; three of the seven gaps found in the file review.
A correction fixes what went wrong this time. A corrective action removes the cause so it does not happen again. A preventive action removes the cause of a problem that has not happened yet, such as the same weakness on another line or path (ISO 13485:2016, 8.5.2 and 8.5.3).
A root cause that ends at a person usually ends too early. The useful question is what let the error through: a screen, a procedure, a route around change control.
Containment looks backwards, for anything else affected before the problem was found. Effectiveness looks forwards, against a criterion written before the check rather than after it.
Adequate is not closed. The plan is accepted; closure waits for evidence that the actions were put in place, and then that they worked against the criterion.
Since 2 February 2026 the FDA’s QMSR (21 CFR 820) incorporates ISO 13485:2016 by reference, so US device makers work to the same CAPA and purchasing clauses.
Contributed sterility assurance expertise to supplier audits and reviewed audit reports, working with suppliers to ensure CAPA responses were adequate and implementation was verified.
Led sterility assurance investigations for nonconformances, CAPAs and isolate identification.